Sanofi (Netherlands)

Recent papers from Sanofi (Netherlands)

1. Characteristics, risk factor profiles, and cardiovascular outcomes in patients with ASCVD without prior ischemic events in Western Europe: The OPTIMUS-RISK StudyEuropean Heart Journal · 2026
2. Patient Perspectives on Non-Hodgkin Lymphoma: A Qualitative Study to Guide Selection of Clinical Trial EndpointsCurrent Oncology · 2026
3. Treatment satisfaction and patient preference for efanesoctocog alfa over previous hemophilia A treatment: Results from the XTEND-1 phase 3 clinical trialCurrent Therapeutic Research · 2026
4. Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Updated analysis incorporating new evidenceVaccine X · 2026
5. From mild-to-moderate to severe asthma: Risk factors and patient profiles from the NORDSTAR cohortAmerican Journal of Respiratory and Critical Care Medicine · 2026
6. Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised studyVaccine · 2026
7. A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemiaCancer Immunology Immunotherapy · 2026
8. Participant satisfaction across three trial arms with varying degrees of decentralisation in the RADIAL proof-of-concept trialTrials · 2026
9. A Psychometric Analysis of the Haemophilia Quality of Life Questionnaire for Adults Physical Health Subscale and Total Scores: Data From the Phase 3 XTEND-1 Trial in Patients With Severe Haemophilia A.2026
10. Estimation of Public Health Impact with Use of Nirsevimab During the 2024–2025 RSV Season in the USA: a Modeling StudyPulmonary Therapy · 2026
11. Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling StudyInfectious Diseases and Therapy · 2026
12. Prurigo Nodularis paTient Reported burdEn of sicKness in Europe (PN TREK Europe): a cross-sectional survey of patient-reported burden of disease in patients with PN from four countries in EuropeJournal of Dermatological Treatment · 2026
13. Impact of Diffusing Lung Capacity for Carbon Monoxide on Mortality Risk in Patients with ASMD: Insights from a Post Hoc AnalysisAdvances in Therapy · 2026
14. Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild‐to‐moderate psoriasisJournal of the European Academy of Dermatology and Venereology · 2026
15. Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysisTherapeutic Advances in Hematology · 2026
16. Insights into immunogenicity and therapeutic strategies to mitigate the immune response in infantile-onset Pompe disease: a comprehensive systematic literature reviewFrontiers in Immunology · 2026
17. Living with advanced or metastatic melanoma: A patient-driven conceptual modelEJC Skin Cancer · 2026
18. Pain Experience in Oncology: A Targeted Literature Review and Development of a Novel Patient-Centric Conceptual ModelCancers · 2025
19. Pain Experience in Oncology: A Targeted Literature Review and Development of a Novel Patient-Centric Conceptual ModelCancers · 2025
20. Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohortExpert Review of Vaccines · 2025